echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ceftriaxone Sodium for Injection, a subsidiary of Shanghai Modern Pharmaceutical, passed the consistency evaluation of generic drugs

    Ceftriaxone Sodium for Injection, a subsidiary of Shanghai Modern Pharmaceutical, passed the consistency evaluation of generic drugs

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 28, Shanghai Modern Pharmaceutical issued an announcement that Sinopharm Zhijun, its holding subsidiary, received the "Notice of Supplementary Application Approval for Drug Supplement Application" approved and issued by the State Food and Drug Administration.


    Ceftriaxone sodium is a long-acting, broad-spectrum third-generation cephalosporin antibiotic.


    According to data from the PDB Drug Comprehensive Database, the global sales of ceftriaxone sodium for injection in 2020 will be US$1.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.